« Back
Home /
Sapacitabine

Sapacitabine

Item no.	HY-16445-50mg
Manufacturer	MedChem Express
CASRN	151823-14-2
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	98.13
Citations	[1]Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36.\|[2]Green SR, et al. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer. 2010 Oct 26;103(9):1391-9.
Smiles	O=C(N=C(NC(CCCCCCCCCCCCCCC)=O)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CS682,CYC682
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Nucleoside Antimetabolite/Analog
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	490.64
Product Description	Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 33.33 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16445-50mg-safety-datasheet.pdf